DT-Web

DB06696 - Arbekacin


Identification
Name Arbekacin
Accession Number DB06696
Type small molecule
Description An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA). Amikacin is also nephrotoxic and ototoxic.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 552.619
Groups approved
Monoisotopic Weight 552.311891658
Pharmacology
Indication Arbekacin is used for the short term treatment of multi-resistant bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA).
Mechanism of action Aminoglycosides, such as Arbekacin, inhibit protein synthesis in susceptible bacteria by irreversibly binding to bacterial 30S and 16S ribosomal subunits. Specifically Arbekacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
Absorption Aminoglycosides are not well absorbed from the gastrointestinal tract. Their absorption is markedly improved by parenteral administration.
Protein binding 3-12%
Biotransformation Not Available
Route of elimination Not Available
Toxicity Ototoxicity and nephrotoxicity are the most serious adverse effects of aminoglycoside therapy and are more likely to occur in patients with a history of renal impairment or who are receiving other ototoxic and/or nephrotoxic drugs. Normal duration of IM or IV aminoglycoside therapy is 7-10 days. Although a longer duration may be necessary in some cases, toxicity is more likely to occur when aminoglycoside treatment is continued for longer than 10 days.
Affected organisms
  • Enteric bacteria and other eubacteria
Interactions
Drug Interactions Not Available
Food Interactions Not Available

Targets


30S ribosomal protein S12
Name 30S ribosomal protein S12
Gene Name rpsL
Pharmacological action yes
Actions inhibitor
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Funatsu G, Yaguchi M, Wittmann-Liebold B: Primary stucture of protein S12 from the small Escherichia coli ribosomal subunit. FEBS Lett. 1977 Jan 15;73(1):12-7. - Pubmed
  • Carter AP, Clemons WM, Brodersen DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V: Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. - Pubmed
DTHybrid score 1.0615

Predictions


Id Partner name Gene Name Score
6704 30S ribosomal protein S12 rpsL 1.0615
4388 Aminoglycoside 2'-N-acetyltransferase aac 0.1234
1162 C-X-C chemokine receptor type 4 CXCR4 0.0691
1244 Low-density lipoprotein receptor-related protein 2 LRP2 0.0525
6028 Kanamycin nucleotidyltransferase knt 0.0448
3390 Aminoglycoside 3'-phosphotransferase aphA 0.0448
6029 Aminoglycoside 3'-phosphotransferase aphA1 0.0448
4240 Protein disulfide-isomerase P4HB 0.0444
1729 Solute carrier family 22 member 6 SLC22A6 0.044
4565 Aminoglycoside 6'-N-acetyltransferase aac(6')-Iy 0.0363
6208 30S ribosomal protein S13 rpsM 0.0281
6706 30S ribosomal protein S13 rpsM 0.0281
6209 30S ribosomal protein S19 rpsS 0.0245
6712 30S ribosomal protein S19 rpsS 0.0245
6726 30S ribosomal protein S19 rpsS 0.0245
6207 30S ribosomal protein S14 rpsN 0.0245
140 30S ribosomal protein S9 rpsI 0.0185
6719 30S ribosomal protein S9 rpsI 0.0185
6725 30S ribosomal protein S9 rpsI 0.0185
↑